(ABOS) Acumen Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 178m USD | Total Return: 159.1% in 12m

Alzheimers Drug, Immunotherapy
Total Rating 48
Safety 63
Buy Signal -0.07
Biotechnology
Industry Rotation: -0.1
Market Cap: 178M
Avg Turnover: 1.41M USD
ATR: 8.60%
Peers RS (IBD): 69.0
Risk 5d forecast
Volatility79.1%
Rel. Tail Risk-8.33%
Reward TTM
Sharpe Ratio1.40
Alpha95.78
Character TTM
Beta1.588
Beta Downside2.466
Drawdowns 3y
Max DD90.73%
CAGR/Max DD-0.13
EPS (Earnings per Share) EPS (Earnings per Share) of ABOS over the last years for every Quarter: "2021-03": -0.94, "2021-06": -7.91, "2021-09": -0.1, "2021-12": -0.42, "2022-03": -0.23, "2022-06": -0.25, "2022-09": -0.26, "2022-12": -0.32, "2023-03": -0.28, "2023-06": -0.28, "2023-09": -0.24, "2023-12": -0.28, "2024-03": -0.25, "2024-06": -0.34, "2024-09": -0.4954, "2024-12": -0.62, "2025-03": -0.48, "2025-06": -0.68, "2025-09": -0.44, "2025-12": -0.41,
EPS CAGR: -11.78%
EPS Trend: -75.1%
Last SUE: 0.34
Qual. Beats: 0
Revenue Revenue of ABOS over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.29, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.178, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: 0.00%
Rev. Trend: 8.2%
Last SUE: 0.00
Qual. Beats: 0

Warnings

Interest Coverage Ratio -22.0 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: ABOS Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company developing treatments for Alzheimers disease. The companys primary focus is Sabirnetug (ACU193), an immunotherapy drug targeting soluble amyloid-beta oligomers.

Sabirnetug has completed Phase 1 and is currently in Phase 2 clinical trials. The biotechnology sector frequently involves lengthy and costly research and development phases, with high risk and potential for significant returns upon successful drug approval. ABOS also has a collaboration with Halozyme, Inc. to develop a subcutaneous formulation of Sabirnetug, indicating a potential strategy to enhance drug delivery and patient convenience.

Further research on ValueRay can provide detailed insights into ABOSs financial performance and pipeline progress.

Headlines to Watch Out For
  • Sabirnetug (ACU193) clinical trial results significantly impact stock valuation
  • Regulatory approval of Alzheimers drug crucial for commercialization
  • Competition in Alzheimers drug development affects market share
  • Collaboration with Halozyme expands drug delivery options
Piotroski VR‑10 (Strict) 0.5
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.94 > 0.02 and ΔFCF/TA -58.05 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.94 > 3% & CFO -115.5m > Net Income -121.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.07 > 1.5 & < 3
Outstanding Shares: last quarter (60.6m) vs 12m ago 0.91% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.07%; Δ -0.07% > 0%)
Interest Coverage Ratio: -21.98 > 6 (EBITDA TTM -118.1m / Interest Expense TTM 4.22m)
Altman Z'' -15.00
A: 0.75 (Total Current Assets 122.3m - Total Current Liabilities 30.0m) / Total Assets 122.8m
B: -3.63 (Retained Earnings -446.5m / Total Assets 122.8m)
C: -0.51 (EBIT TTM -92.8m / Avg Total Assets 180.9m)
D: -8.52 (Book Value of Equity -446.4m / Total Liabilities 52.4m)
Altman-Z'' Score: -19.31 = D
What is the price of ABOS shares? As of April 16, 2026, the stock is trading at USD 2.72 with a total of 337,454 shares traded.
Over the past week, the price has changed by +5.43%, over one month by -18.56%, over three months by +46.24% and over the past year by +159.05%.
Is ABOS a buy, sell or hold? Acumen Pharmaceuticals has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy ABOS.
  • StrongBuy: 5
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ABOS price?
Analysts Target Price 7.4 172.1%
Acumen Pharmaceuticals (ABOS) - Fundamental Data Overview as of 13 April 2026
P/S = 538.7842
P/B = 2.5325
Revenue TTM = 0.0 USD
EBIT TTM = -92.8m USD
EBITDA TTM = -118.1m USD
Long Term Debt = 22.4m USD (from longTermDebt, last quarter)
Short Term Debt = 8.91m USD (from shortTermDebt, last quarter)
Debt = 31.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -85.6m USD (recalculated: Debt 31.3m - CCE 116.9m)
Enterprise Value = 92.8m USD (178.4m + Debt 31.3m - CCE 116.9m)
Interest Coverage Ratio = -21.98 (Ebit TTM -92.8m / Interest Expense TTM 4.22m)
EV/FCF = -0.80x (Enterprise Value 92.8m / FCF TTM -115.6m)
 FCF Yield = -124.6% (FCF TTM -115.6m / Enterprise Value 92.8m)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 90.0k) / Revenue TTM)
 Tobins Q-Ratio = 0.76 (Enterprise Value 92.8m / Total Assets 122.8m)
Interest Expense / Debt = 3.47% (Interest Expense 1.09m / Debt 31.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -73.3m (EBIT -92.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.07 (Total Current Assets 122.3m / Total Current Liabilities 30.0m)
Debt / Equity = 0.44 (Debt 31.3m / totalStockholderEquity, last quarter 70.4m)
 Debt / EBITDA = 0.72 (negative EBITDA) (Net Debt -85.6m / EBITDA -118.1m)
 Debt / FCF = 0.74 (negative FCF - burning cash) (Net Debt -85.6m / FCF TTM -115.6m)
 Total Stockholder Equity = 109.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.07% (Net Income -121.3m / Total Assets 122.8m)
RoE = -111.3% (Net Income TTM -121.3m / Total Stockholder Equity 109.1m)
RoCE = -70.62% (EBIT -92.8m / Capital Employed (Equity 109.1m + L.T.Debt 22.4m))
 RoIC = -52.70% (negative operating profit) (NOPAT -73.3m / Invested Capital 139.2m)
 WACC = 10.24% (E(178.4m)/V(209.7m) * Re(11.56%) + D(31.3m)/V(209.7m) * Rd(3.47%) * (1-Tc(0.21)))
Discount Rate = 11.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.17%
 [DCF] Fair Price = unknown (Cash Flow -115.6m)
 EPS Correlation: -75.14 | EPS CAGR: -11.78% | SUE: 0.34 | # QB: 0
Revenue Correlation: 8.18 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.46 | Chg7d=-0.460 | Chg30d=-0.460 | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=-1.88 | Chg7d=+0.053 | Chg30d=+0.053 | Revisions Net=+1 | Growth EPS=+5.9% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-1.39 | Chg7d=+0.416 | Chg30d=+0.416 | Revisions Net=+1 | Growth EPS=+26.1% | Growth Revenue=+0.0%
External Resources
Dataroma Stockcircle